West Pharmaceutical Services Reports Q2 Adj EPS Of $1.25.
WEST ANNOUNCES SECOND-QUARTER 2020 RESULTS.
Q2 ADJUSTED EARNINGS PER SHARE $1.25.
Q2 EARNINGS PER SHARE $1.21.
SEES FY 2020 SALES $2.035 BILLION TO $2.055 BILLION.
Q2 SALES $527.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $496.1 MILLION.
RAISING FULL-YEAR 2020 ADJUSTED-DILUTED EPS GUIDANCE TO A NEW RANGE OF BETWEEN $4.15 AND $4.25.
SEES 2020 ORGANIC SALES GROWTH TO BE APPROXIMATELY 12%.
WEST PHARMACEUTICAL SERVICES - NET SALES GUIDANCE INCLUDES ESTIMATED FULL-YEAR HEADWIND OF $26 MILLION FOR 2020 BASED ON CURRENT FOREIGN EXCHANGE RATES.
